CC-42344 - Influenza A PB2 Inhibitor
| Program | Discovery | Preclinical | Phase 1 | Phase 2a | Phase 2b | Phase 3 | |
|---|---|---|---|---|---|---|---|
| Influenza A | CC-42344 PB2 Inhibitor |
Discovery Phase complete
|
Preclinical Phase complete
|
Phase 1 Phase in progress
|
Phase 2a Phase not started
|
Phase 2b Phase not started
|
Phase 3 Phase not started
|
CC-42344, our novel, broad-spectrum, orally administered antiviral investigational candidate for a potential treatment of pandemic and seasonal influenza A infection. It binds to a highly conserved PB2 site of influenza A polymerase complex and exhibits a novel mechanism of action which inhibits replication. We began enrolling subjects in a Phase 1 study with CC-42344 for the treatment of pandemic and seasonal influenza A in the first quarter of 2022. The study is being conducted in Australia and is designed to assess the safety, tolerability and pharmacokinetics of CC-42344 with results expected in 2022.
In vitro testing showed CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu® and Xofluza™, while also demonstrating favorable pharmacokinetic and safety profiles. CC-42344 inhibits the first step in influenza A’s viral replication by binding to a highly conserved PB2 site of the influenza polymerase complex that is essential to replication. We discovered CC-42344 using our proprietary structure-based drug discovery platform technology.